Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015)
- Authors:
- Bell, Richard
- Brown, Julia
- Parmar, Mahesh
- Toi, Mark
- Suter, Thomas
- Steger, Guenther
- Pivot, Xavier
- Mackey, John
- Jackisch, Christian
- Dent, Rebecca
- Hall, Peter
- Mecke, Almut
- Morales, Leilani
- Provencher, Louise
- Staroslawska, Elzbieta
- Hegg, Roberto
- Vanlemmens, Laurence
- Kirsch, Andreas
- Schneeweiss, Andreas
- Masuda, Norikazu
- Overkamp, Friedrich
- Cameron, David
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1158/1538-7445.SABCS14-PD2-2
- Subjects: QUIMIOTERAPIA; NEOPLASIAS MAMÁRIAS (TERAPIA); ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 75, abst. PD2-2, May, 2015
- Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
BELL, Richard et al. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2. Acesso em: 13 jan. 2026. , 2015 -
APA
Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G., et al. (2015). Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-PD2-2 -
NLM
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2026 jan. 13 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2 -
Vancouver
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2026 jan. 13 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2 - Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Recursos terapêuticos na doente terminal
- Terapia estrogenica e cancer de mama
- Fatores prognósticos do câncer de mama
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Informações sobre o DOI: 10.1158/1538-7445.SABCS14-PD2-2 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
